Recursion Pharmaceuticals Expands Citeline Partnership to Boost AI Drug Discovery

The biotech firm aims to leverage real-world data to improve clinical trial design and development decisions.

Apr. 19, 2026 at 8:51pm

Got story updates? Submit your updates here. ›

A minimalist, photorealistic studio still-life featuring a collection of polished, geometric objects arranged on a clean, monochromatic background, symbolizing the integration of real-world data and advanced analytics into Recursion's AI-driven drug discovery platform.Recursion Pharmaceuticals' expanded partnership with Citeline aims to leverage real-world data and analytics to enhance the efficiency of its AI-powered drug discovery efforts.Salt Lake City Today

Recursion Pharmaceuticals, a clinical-stage biotech company using AI and machine learning to accelerate drug discovery, has expanded its partnership with Citeline, a leading provider of data and analytics to the life sciences industry. Through this expanded deal, Recursion will integrate Citeline's real-world data capabilities into its AI-driven platform to enhance its drug development process.

Why it matters

Recursion is at the forefront of leveraging advanced technologies like AI to streamline the notoriously lengthy and costly drug development cycle. By adding Citeline's real-world data to its platform, Recursion aims to make more informed decisions around clinical trial design and drug candidate progression, potentially reducing time and costs. This partnership is a strategic move to bolster Recursion's competitive edge in the rapidly evolving AI-for-drug-discovery space.

The details

Under the expanded agreement, Recursion will incorporate Citeline's extensive database of real-world patient data and analytics into its proprietary AI platform. This integration is intended to help Recursion make more data-driven decisions throughout the drug development process, from optimizing clinical trial protocols to identifying the most promising drug candidates. Recursion, which has a large pipeline of both wholly owned and partnered drug programs, believes this enhanced data and analytics capability will improve the efficiency and success rate of its R&D efforts.

  • On March 31, 2026, Recursion announced the expanded partnership with Citeline.
  • At the end of 2025, Recursion had over $500 million in milestone payments from its partnered programs and $754 million in cash reserves.

The players

Recursion Pharmaceuticals Inc

A clinical-stage biotechnology company based in Salt Lake City, Utah that uses artificial intelligence, machine learning, and other advanced technologies to accelerate drug discovery and development.

Citeline

A leading provider of data, analytics, and insights to companies in the life sciences and pharmaceutical industries.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Recursion's expanded partnership with Citeline underscores the company's commitment to leveraging advanced data and analytics capabilities to drive innovation in drug discovery. By integrating real-world patient data into its AI platform, Recursion aims to make more informed decisions and improve the efficiency of its R&D efforts, positioning it as a leader in the rapidly evolving field of AI-powered drug development.